Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMXKOW6)

Drug Name
MKC-1106-MT Drug Info
Synonyms Melanoma vaccine (MART-1/tyrosinase), Mannkind
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMXKOW6

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
MART-1 melanoma antigen (MLANA) TT362RB MAR1_HUMAN Modulator [2]
Tyrosinase (TYR) TTULVH8 TYRO_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Tyrosinase (TYR) DTT TYR 5.959 5.711 5.973 4.912
MART-1 melanoma antigen (MLANA) DTT MLANA 5.361 5.115 4.926 4.954
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Skin
The Studied Disease Melanoma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tyrosinase (TYR) DTT TYR 6.68E-04 2.54 1.15
MART-1 melanoma antigen (MLANA) DTT MLANA 3.29E-02 1.64 0.76
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01026051) Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma. U.S. National Institutes of Health.
2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.